<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262690</url>
  </required_header>
  <id_info>
    <org_study_id>B2291001</org_study_id>
    <secondary_id>TAM-163 FIH Study; 3279K1-1000</secondary_id>
    <nct_id>NCT01262690</nct_id>
  </id_info>
  <brief_title>A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin</brief_title>
  <official_title>A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether a single dose of PF-05230901 is safe and well tolerated when
      given to healthy volunteers by injection under the skin. An additional objective is to
      measure the blood concentrations of PF-05230901. Each dose will be tested in a different
      group of subjects starting from the lowest dose.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated on 21-Sept-2011 due to the emergent safety concern of sensory
    symptoms.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of clinical laboratory abnormalities.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in vital signs.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in 12-lead electrocardiogram (ECG) parameters.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of findings during the neurological examination.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite and food consumption</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Cachexia</condition>
  <arm_group>
    <arm_group_label>Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 treated, 3 placebos</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05230901</intervention_name>
    <description>Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.</description>
    <arm_group_label>Dose</arm_group_label>
    <other_name>TAM-153</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05230901</intervention_name>
    <description>Single dose SC</description>
    <arm_group_label>Dose</arm_group_label>
    <other_name>TAM-163</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

        Exclusion Criteria:

          -  History of seizures, including childhood seizures.

          -  History of movement disorders or related neurological conditions.

          -  History of head trauma associated with loss of consciousness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2291001&amp;StudyName=A%20Study%20In%20Healthy%20Subjects%20Of%20Single%20Doses%20of%20PF-05230901%20Injected%20Under%20The%20Skin</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>October 11, 2011</last_update_submitted>
  <last_update_submitted_qc>October 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-human (FIH)</keyword>
  <keyword>Single Ascending Dose (SAD) Study</keyword>
  <keyword>TAM-163</keyword>
  <keyword>PF-05230901</keyword>
  <keyword>Cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

